非肌层浸润性膀胱癌的膀胱内治疗:系统综述与Meta分析
该系统综述与Meta分析检索了Ovid MEDLINE(1990年1月至2016年2月)等数据库,纳入39项比较辅助膀胱内治疗与单纯经尿道膀胱肿瘤电切的试验及55项膀胱内药物头对头试验。结果显示卡介苗可降低复发风险(RR 0.56)和进展风险(RR 0.39),但局部和全身不良事件发生率更高;卡介苗与丝裂霉素C在复发风险上无差异(RR 0.95)。
要点
- 卡介苗降低膀胱癌复发风险(RR 0.56)和进展风险(RR 0.39),证据强度低。
- 卡介苗与丝裂霉素C复发风险无差异(RR 0.95),维持方案亚组中卡介苗降低复发风险(RR 0.79)。
- 卡介苗局部和全身不良事件发生率高于其他膀胱内药物,证据强度低。
核心结论
- 多种膀胱内治疗与单纯经尿道膀胱肿瘤电切相比可降低非肌层浸润性膀胱癌复发风险。
- 卡介苗是唯一与单纯经尿道膀胱肿瘤电切相比降低进展风险的药物,但不良事件风险可能高于其他膀胱内治疗,提示获益与风险之间存在权衡。
研究设计与样本
- 系统综述与Meta分析,检索Ovid MEDLINE(1990年1月至2016年2月)、Cochrane数据库及参考文献列表。
- 纳入膀胱内卡介苗、丝裂霉素C、吉西他滨、噻替哌、戊柔比星、多柔比星、表柔比星和干扰素对比单纯经尿道膀胱肿瘤电切的随机及半随机试验,以及膀胱内治疗的头对头试验。
- 共39项试验评估辅助膀胱内治疗对比单纯经尿道膀胱肿瘤电切,55项试验比较不同膀胱内治疗药物。
- 采用随机效应模型合并数据。
主要发现
- 卡介苗与膀胱癌复发风险降低相关(3项试验,RR 0.56,95% CI 0.43-0.71),与进展风险降低相关(4项试验,RR 0.39,95% CI 0.24-0.64),证据强度低。
- 丝裂霉素C、多柔比星、表柔比星和噻替哌也与复发风险降低相关,进展风险无差异,证据强度低。
- 卡介苗与丝裂霉素C在复发风险上无差异(RR 0.95,95% CI 0.81-1.11),但在维持方案试验亚组中卡介苗与复发风险降低相关(RR 0.79,95% CI 0.71-0.87,证据强度低)。
- 卡介苗与多柔比星、表柔比星、干扰素α-2a、卡介苗联合干扰素α-2b及噻替哌相比复发风险更低,证据强度低至中等。
- 卡介苗局部和全身不良事件发生率高于其他膀胱内药物,证据强度低。
关键数值与推荐
- 卡介苗对比单纯经尿道膀胱肿瘤电切:复发风险RR 0.56(95% CI 0.43-0.71,3项试验),进展风险RR 0.39(95% CI 0.24-0.64,4项试验),证据强度低。
- 卡介苗对比丝裂霉素C:复发风险RR 0.95(95% CI 0.81-1.11),无差异。
- 卡介苗对比丝裂霉素C维持方案亚组:复发风险RR 0.79(95% CI 0.71-0.87),证据强度低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 卡介苗对比单纯经尿道膀胱肿瘤电切的复发和进展证据强度为低。
- 丝裂霉素C、多柔比星、表柔比星和噻替哌对比单纯经尿道膀胱肿瘤电切的复发证据强度为低。
- 卡介苗对比其他膀胱内药物复发风险的证据强度为低至中等。
- 卡介苗不良事件风险的证据强度为低。
- 卡介苗标准剂量与低剂量头对头试验在复发、进展或死亡风险上无明确差异,证据强度低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We systematically review the benefits and harms of intravesical therapies for nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Systematic literature searches were performed of Ovid MEDLINE (January 1990 through February 2016), the Cochrane databases and reference lists. Randomized and quasi-randomized trials of intravesical bacillus Calmette-Guérin, mitomycin C, gemcitabine, thiotepa, valrubicin, doxorubicin, epirubicin and interferon vs transurethral bladder tumor resection alone, and head-to-head trials of intravesical therapies were selected. Data were pooled using a random effects model. RESULTS: Overall 39 trials evaluated adjuvant intravesical therapy vs transurethral bladder tumor resection alone. Bacillus Calmette-Guérin was associated with a decreased risk of bladder cancer recurrence (3 trials, RR 0.56, 95% CI 0.43-0.71) and progression (4 trials, RR 0.39, 95% CI 0.24-0.64) (strength of evidence low). Mitomycin C, doxorubicin, epirubicin and thiotepa were also associated with a decreased risk of recurrence, with no difference in risk of progression (strength of evidence low). There were 55 trials that compared one intravesical therapy agent against another. There were no differences between bacillus Calmette-Guérin vs mitomycin C in recurrence risk (RR 0.95, 95% CI 0.81-1.11), but bacillus Calmette-Guérin was associated with a decreased risk of recurrence in the subgroup of trials of maintenance regimens (RR 0.79, 95% CI 0.71-0.87, strength of evidence low). Bacillus Calmette-Guérin was associated with a lower recurrence risk vs doxorubicin, epirubicin, interferon alpha-2a, bacillus Calmette-Guérin plus interferon alpha-2b, and thiotepa (strength of evidence low to moderate). Bacillus Calmette-Guérin was associated with higher rates of local and systemic adverse events than other intravesical agents (strength of evidence low). Head-to-head trials showed no clear differences between standard and lower doses of bacillus Calmette-Guérin in recurrence, progression or mortality risk (strength of evidence low). Limited evidence suggested that bacillus Calmette-Guérin maintenance regimens are associated with reduced recurrence risk vs no further intravesical therapy in responders to induction therapy (strength of evidence low). CONCLUSIONS: For nonmuscle invasive bladder cancer several intravesical therapies are associated with a decreased risk of recurrence vs transurethral bladder tumor resection alone. Bacillus Calmette-Guérin is the only agent associated with a decreased progression risk vs transurethral bladder tumor resection alone, but may be associated with a higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms.
引用
- Chou R, Selph S, Buckley DI, et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol. 2016. PMID: 28027868. doi:10.1016/j.juro.2016.12.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。